rawfin.tv
Amgen Reports Positive Phase 3 Trial Results for IMDELLTRA
Marketsstocks🟠 Score 8AI Generated

Amgen Reports Positive Phase 3 Trial Results for IMDELLTRA

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Amgen announced landmark results from its Phase 3 DeLLphi-305 study, demonstrating statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA in combination with Imfinzi. These positive findings are expected to bolster the company's oncology pipeline and market position.

AmgenClinical TrialsPharmaceuticalsOncologyStock PerformanceDrug Development

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks